Viking Therapeutics (VKTX) Competitors

Genmab A/S (NASDAQ:GMAB) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.

Does the MarketBeat Community believe in GMAB or VKTX?

Viking Therapeutics received 468 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 80.08% of users gave Viking Therapeutics an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%
Viking Therapeutics	Outperform Votes 635 80.08%	Underperform Votes 158 19.92%

Do analysts prefer GMAB or VKTX?

Genmab A/S currently has a consensus target price of $39.17, suggesting a potential upside of 94.09%. Viking Therapeutics has a consensus target price of $87.15, suggesting a potential upside of 216.92%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Viking Therapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Is GMAB or VKTX more profitable?

Genmab A/S has a net margin of 36.30% compared to Viking Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 16.78% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
Viking Therapeutics	N/A	-11.93%	-11.57%

Do institutionals and insiders believe in GMAB or VKTX?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has preferable earnings & valuation, GMAB or VKTX?

Genmab A/S has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.15	$1.14B	$1.76	11.47
Viking Therapeutics	N/A	N/A	-$109.96M	-$1.15	-23.91

Which has more volatility & risk, GMAB or VKTX?

Genmab A/S has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Does the media favor GMAB or VKTX?

In the previous week, Genmab A/S had 12 more articles in the media than Viking Therapeutics. MarketBeat recorded 25 mentions for Genmab A/S and 13 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.41 beat Genmab A/S's score of 0.65 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S and Viking Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.